Nevada's only bone marrow transplant program welcomes new physician
Dr. Carolyn Mulroney brings a wealth of experience to the role of Medical Director of MountainView's TCT progrm.
MountainView Hospital welcomes Dr. Carolyn Mulroney to its Sarah Cannon Transplant & Cellular Therapy (TCT) Program at MountainView Hospital.
Dr. Mulroney is a board-certified hematologist with Sarah Cannon Transplant and Cellular Therapy Program at MountainView Hospital. She brings more than 30 years of diverse experience and skills in the fields of oncology and hematology, including cellular therapy and hematopoietic stem cell transplant. She has completed board certifications in hematology, medical oncology and internal medicine.
Dr. Mulroney joins the TCT program (commonly referred to as bone marrow transplant, or BMT) at MountainView as the Medical Director. The program is the only such program in the state of Nevada and has received internationally-recognized accreditation by the Foundation for the Accreditation of Cellular Therapy (FACT) for adult autologous transplantation and immune effector cell therapy (IECT).
“I am pleased to introduce and welcome Dr. Mulroney to MountainView Hospital and our Las Vegas community,” said Hiral Patel, MountainView Hospital Chief Executive Officer. “Dr. Mulroney’s extensive experience in blood cancers and TCT therapies and transplants not only strengthens our medical team, but also exemplifies our commitment to providing cutting-edge treatments and compassionate care. We are excited to have her join us as we continue to serve the health needs of our community with excellence and dedication.”
Dr. Mulroney has extensive experience in treating hematologic malignancies, other nonmalignant blood disorders, and in providing hematopoietic transplant and cellular therapy in these settings.
Prior to joining MountainView, Dr. Mulroney served as the Clinical Director of the Blood and Marrow Transplant Program at UCSD/Sharp Healthcare Program.
Dr. Mulroney has authored numerous research articles and abstracts. She is a member of several professional societies including American Society of Hematology, American Society for Blood and Marrow Transplantation, and Association for the Advancement of Blood and Biotherapies, among others.
"I am excited to collaborate with our community physicians in providing exceptional care for patients battling blood cancers," said Dr. Mulroney. "MountainView Hospital's unwavering dedication to oncology care shines through in every aspect of their work."
The Sarah Cannon Transplant & Cellular Therapy Program at MountainView Hospital includes an inpatient unit and outpatient clinic. As part of the Sarah Cannon Transplant & Cellular Therapy Network, programs are brought together through physician-led blood cancer programs across the United States and United Kingdom and is one of the largest providers of transplant and cellular therapies in the world.
The Sarah Cannon Transplant & Cellular Therapy Program at MountainView Hospital is part of the Sarah Cannon Transplant & Cellular Therapy Network, offering patients convenient, community-based access to complex blood cancer care including acute leukemia, blood and marrow transplantation, clinical trials and innovative therapies. The Network treats approximately 1,600 transplant and cellular therapy patients annually across its nine FACT/JACIE accredited programs in the United States and United Kingdom.
Patients and physicians who want to learn more about MountainView’s program can call (702) 962-2106.